Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Attiki: International Institute of Anticancer Research
Erscheinungsjahr
2004
Quelle
MEDLINE
Beschreibungen/Notizen
Background: Recurrence of drug-resistant disease contributes to the high mortality of ovarian cancer patients, which necessitates
the identification of additional chemotherapeutic drugs. Histone deacetylase inhibitors (HDAIs) induce apoptosis in a number
of malignant cell types and may represent a new class of drugs clinically relevant in the treatment of ovarian cancer. Materials
and Methods: Ovarian cancer cells were treated with various combinations of a HDAI and paclitaxel (PTX). Cell death was measured
using annexin V / propidium iodide exclusion. Results: The PTX/HDAI drug combination was as efficient in inducing cell death
as continuous PTX treatment and superior to continuous HDAI treatment. Reversing the sequence of drug exposure reduced the
cytotoxic efficacy of the drug combination. The p53 status of the cell lines did not alter the cytotoxic efficacy of the treatment
protocols. Conclusion: These results suggest that HDAIs possess possible clinical applications as an adjuvant therapy in the
treatment of ovarian cancer.